Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer’s Finerenone Marches Forward, But Is Phase III Design Too Steep A Hill?

This article was originally published in The Pink Sheet Daily

Executive Summary

Heart failure drug's safety profile should become more clear – if the two-indication program hits the mark on dose selection and the evolving standard of care.

Advertisement

Related Content

Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel